A STUDY OF EFFICACY OF PEMETREXED BASED CHEMOTHERAPY IN ADVANCE MALIGNANT PLEURAL MESOTHELIOMA

ANKIT AGARWAL; RAMESH PUROHIT; AJAY YADAV; SHASHANK KOTHARI; AVI SHAH; ASHISH JAKHETIYA; RENU MISHRA

doi:10.22159/ajpcr.2024v17i11.52747

Authors

ANKIT AGARWAL Department of Medical Oncology, Geetanjali Medical college, Udaipur, Rajasthan, India
RAMESH PUROHIT Department of Radiation Oncology, Geetanjali Medical College, Udaipur, Rajasthan, India https://orcid.org/0000-0002-5222-292X
AJAY YADAV Department of Surgical Oncology, Geetanjali Medical College, Udaipur, Rajasthan, India https://orcid.org/0009-0000-5780-1288
SHASHANK KOTHARI Department of Radiation Oncology, Geetanjali Medical College, Udaipur, Rajasthan, India https://orcid.org/0000-0001-6194-074X
AVI SHAH Department of Medical Oncology, Geetanjali Medical college, Udaipur, Rajasthan, India https://orcid.org/0000-0003-1656-2852
ASHISH JAKHETIYA Department of Surgical Oncology, Geetanjali Medical College, Udaipur, Rajasthan, India
RENU MISHRA Department of Medical Oncology, Geetanjali Medical college, Udaipur, Rajasthan, India

DOI:

https://doi.org/10.22159/ajpcr.2024v17i11.52747

Keywords:

Advanced pleural mesothelioma, Pemetrexed based chemotherapy, OMCT

Abstract

Objectives: To study Clinicopathological profile & treatment outcomes of stage IV Malignant pleural mesothelioma (MPM) cases.

Material and methods: The data obtained retrospectively was recorded in preformed proforma. Age, gender, hometown, residence, asbestos usage history, latent period between asbestos exposure and diagnosis, symptoms, histopathological type, stage, karnofsky performance (KPS), treatment regimen, survival were all recorded. Staging was done after histopathological confirmation of diagnosis using thoracic & abdominal Computed tomography, and/or PET CT. Patients were either treated with chemotherapy or immunotherapy.

Results: 124 patients were diagnosed with MPM stage IV. Out of these 124 patients, 23 patients received only Oral metronomic chemotherapy (OMCT) due to poor Performance status (PS), 33 patients lost to follow up, 15 patients were given immunotherapy, and 53 patients were given palliative chemotherapy (pemetrexed plus carboplatin or cisplatin every 21 days until progression or intolerability). The median age at diagnosis was 63 years (41 yrs to 79 yrs). The male: female ratio was 2:1. Patients on palliative chemotherapy had response rate of 55% (29 patients out of 53 patients responded to chemotherapy). Median PFS and median OS for those patients on palliative chemotherapy was 3.9 months and 9.1 months respectively. The patients on OMCT had response rate of 27%, median PFS of 2.7 months and median OS of 6.9 months.

Conclusion: We conclude that Advanced pleural mesothelioma has overall poor survival outcomes. Palliative pemetrexed based chemotherapy has shown better survival benefits in terms of OS & PFS as compared to OMCT alone.

Downloads

Download data is not yet available.

References

Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: A review. MedGenMed. 2007;9(2):32.

Bianchi C, Bianchi T. Malignant mesothelioma: Global incidence and relationship with asbestos. Ind Health. 2007;45(3):379-387.

Boffetta P. Epidemiology of peritoneal mesothelioma: A review. Ann Oncol. 2007;18(6):985-990.

De Pangher Manzini V. Malignant peritoneal mesothelioma. Tumori. 2005;91:1-5.

Ahmed I, Koulaouzidis A, Iqbal J, Tan WC. Malignant peritoneal mesothelioma as a rare cause of ascites: A case report. J Med Case Rep. 2008;2:121.

Teta MJ, Mink PJ, Lane E. US mesothelioma pattern 1973-2002: Indicators of change and insights into background rate. Eu J Cancer Prev. 2008;17:525.

Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax. 1976;31:15-24.

Ceresoli GL, Chiti A, Zucali PA, Cappuzzo F, De Vincenzo F, Cavina R, et al. Assessment of tumor response in malignant pleural mesothelioma. Cancer Treat Rev. 2007;33:533-41.

Yazicioglu S, Ilçayto R, Balci K, Sayli BS, Yorulmaz B. Pleural calcification, pleural mesotheliomas, and bronchial cancers caused by tremolite dust. Thorax. 1980;35:564-9.

Hillerdal G. Mesothelioma: Cases associated with non-occupational and low dose exposures. Occup Environ Med. 1999;56:505-13.

Senyiğit A, Bayram H, Babayiğit C, Topçu F, Nazaroğlu H, Bilici A, et al. Malignant pleural mesothelioma caused by environmental exposure to asbestos in the Southeast of Turkey: CT findings in 117 patients. Respiration. 2000;67:615-22.

Chanana R, Prabhash K, Noronha V, Joshi A, Patil VM, Nakti D. P2- 122 Retrospective study to evaluate treatment outcomes of pleural mesothelioma treated in a tertiary care centre in India. Ann Oncol. 2018;29:vii75-6.